Report Highlights

South America Smart Inhalers: Market Overview

The smart inhalers market in South America reached USD 148.6 million in 2024, shaped almost entirely by the burden of respiratory disease and the public health infrastructure established to address it. Brazil and Colombia together account for roughly 72% of regional demand, with Brazil's Sistema Único de Saúde (SUS) acting as the single most powerful procurement force. The market's current structure reflects a hybrid model: government-funded programmes define volume and product eligibility, while private health insurers such as Bradesco Saúde and SulAmérica drive premium-tier adoption of companion digital platforms in urban centres.

Private sector leadership has been largely confined to product development, distribution logistics, and digital platform innovation, while governments retain control over formulary access, pricing ceilings, and procurement volumes. Regional underdevelopment in connectivity infrastructure across rural Andean and Amazonian zones continues to constrain the total addressable market, limiting smart inhaler functionality in areas where Bluetooth pairing and application synchronisation are unreliable. Despite this, year-on-year growth has been consistent since 2021, driven by rising asthma prevalence rates — estimated at 13% of the Brazilian population by the Brazilian Thoracic Society — and an expanding chronic disease management mandate within national health policies.

Policy-Driven Growth in Smart Inhalers across South America

Brazil's Lei nº 9.656/1998 on health plan coverage, updated through ANS Normativa 465/2021, mandates that registered health plans cover inhaler-based respiratory therapies, indirectly creating a reimbursable pathway for smart inhaler prescriptions when devices carry ANVISA registration. More directly, the Programa Farmácia Popular, administered by the Ministry of Health, subsidises inhaler drug acquisition for low-income patients, with smart inhaler-compatible formulations progressively being added to the programme's 2024 updated formulary. This subsidy mechanism reduces patient cost at the point of dispensing and expands the installed base of eligible devices at the population level.

In Colombia, MINSALUD's Resolución 3280 of 2018 and its 2022 update embedded digital adherence monitoring as a recommended practice within the national COPD and asthma clinical guidelines, creating institutional demand for connected devices through EPS (Entidades Promotoras de Salud) procurement cycles. Chile's Garantías Explícitas en Salud (GES) plan — which legally guarantees treatment for bronchial asthma in patients under 15 and adults over 50 — creates a mandated procurement volume that CENABAST must fulfil, and connected device specifications were formally introduced into GES technical annexes in 2023. Argentina's Programa SUMAR, targeting uninsured populations, added respiratory disease management modules in 2022, providing a procurement entry point for lower-cost smart inhaler models in the provinces.

Regulatory Barriers and Compliance Costs

ANVISA, Brazil's Agência Nacional de Vigilância Sanitária, classifies smart inhalers as Class III medical devices under RDC 751/2022, requiring full technical dossier submission, software lifecycle documentation per IEC 62304, and cybersecurity assessments. The registration process, even under the expedited pathway, involves a minimum 9-month review cycle and pre-submission fees exceeding BRL 80,000 (approximately USD 16,000) before any in-country clinical or technical validation begins. Companies must also maintain a Brazilian legal representative (Responsável Técnico) under CFM and CRF regulations, adding permanent operational overhead. Foreign manufacturers face additional layers of documentation legalisation through apostille requirements before ANVISA will accept submissions.

Colombia's INVIMA classifies connected inhalers under the Dispositivos Médicos framework established by Decreto 4725/2005 and requires local manufacturing or importation permits, with registration timelines averaging 14 months for Class IIb devices. Argentina's ANMAT, operating under Disposición 2318/2002 and subsequent amendments, enforces price notification requirements under the Observatorio de Precios that limit commercial flexibility on devices entering public procurement channels. Local content requirements are not formally mandated in most South American jurisdictions, but practical procurement preference clauses in Brazil's Lei nº 8.666/1993 — and its successor, Lei nº 14.133/2021 — award scoring advantages to bids that demonstrate domestic assembly or supply chain participation, penalising fully imported device propositions in government tenders.

Policy-Created Opportunities in South America

Brazil's Estratégia de Saúde Digital (ESD 2020–2028), coordinated by DATASUS and the Ministry of Health, mandates interoperability standards for digital health devices connecting to the Rede Nacional de Dados em Saúde (RNDS). Smart inhalers that achieve RNDS-compatible data integration qualify for inclusion in federal digital health procurement frameworks, an opportunity that no commercially available smart inhaler has fully exploited as of 2025. The ESD allocates BRL 1.2 billion over its programme duration for digital health integration infrastructure, and device manufacturers that develop certified RNDS connectors will gain first-mover access to public hospital procurement networks serving over 4,500 SUS facilities nationwide.

Chile's 2023 Plan Nacional de Salud Digital and Colombia's MINSALUD Digital Health Policy Resolution 866/2021 both create subsidised demand for interoperable chronic disease monitoring devices in primary care settings. Chile's FONDO Nacional de Salud (FONASA) is actively evaluating connected inhaler coverage under its Modalidad de Libre Elección benefit tier, with a formal coverage decision expected in 2026. In Argentina, the recent passage of Ley 27.553 on digital prescriptions and remote health services creates a legal and operational infrastructure for remote inhaler monitoring, removing a previous regulatory gap that had blocked telehealth-integrated smart inhaler programmes from operating in the public sector.

Market at a Glance

Leading Market Participants

• AstraZeneca
• Boehringer Ingelheim
• Philips Respironics
• Propeller Health (ResMed)
• Adherium
• GlaxoSmithKline
• Novartis
• Teva Pharmaceutical Industries
• Chiesi Farmaceutici
• 3M Health Care

Regulatory and Policy Environment

The primary regulatory instrument governing smart inhalers in South America's largest market is ANVISA's Resolução da Diretoria Colegiada RDC 751/2022, which replaced the older RDC 185/2001 framework and introduced specific provisions for software-as-a-medical-device (SaMD) components embedded in connected devices. This regulation requires manufacturers to submit a Software Lifecycle Plan under IEC 62304, a risk management file per ISO 14971:2019, and usability engineering documentation per IEC 62366-1. ANVISA's Gerência-Geral de Tecnologia em Serviços de Saúde (GGTES) is the responsible directorate. A major upcoming change is ANVISA's planned 2026 revision to incorporate MDR-aligned post-market surveillance requirements, which will obligate manufacturers to submit periodic safety update reports (PSURs) for all Class III devices, increasing ongoing compliance costs.

Compared to regional peers, Brazil's regulatory framework is the most developed and demanding. Colombia's INVIMA operates under a 2005-era decree structure currently under revision, with a new Política Nacional de Dispositivos Médicos expected to be enacted by late 2025 that will introduce software device classifications for the first time. Chile's ISP (Instituto de Salud Pública) maintains a comparatively streamlined registration process — averaging 8 months for equivalent device classes — giving Chile a regulatory speed advantage that multinational manufacturers have begun to exploit as a regional entry gateway. Argentina's ANMAT remains the most commercially restrictive regulator due to its price notification regime, which effectively caps private market margins and discourages premium device launches outside reimbursed public channels.

Long-Term Policy Outlook for South America's Smart Inhalers Market

By 2032, the most consequential policy development will be the full operationalisation of Brazil's RNDS interoperability mandate, which is scheduled to extend to outpatient chronic disease devices under the ESD 2020–2028 second phase, due for implementation in 2027. This will create a regulatory requirement — not merely an opportunity — for smart inhalers distributed through SUS to transmit adherence and usage data directly into the national health data network. Manufacturers that have not built RNDS-compliant firmware and data architecture by 2026 will face market exclusion from the single largest public procurement channel in South America, reshaping the competitive landscape entirely in favour of digitally integrated device platforms.

Colombia is expected to implement universal health coverage reforms under the Ley Estatutaria 1751/2015 enforcement agenda that will expand EPS-mandated digital disease management coverage by 2028, adding an estimated 4.2 million new COPD and asthma patients to reimbursed care pathways where connected devices will be eligible for procurement. Chile's anticipated FONASA coverage decision for smart inhalers in 2026 will set a regional pricing precedent that other Andean markets will reference in their own reimbursement negotiations. Across the region, the convergence of digital health mandates, expanding insurance coverage of chronic respiratory disease, and escalating COPD burden from persistent urban air quality failures in cities such as Santiago, Bogotá, and São Paulo will sustain above-market growth through the entire forecast period.

Market Segmentation

By Product Type

• Smart Metered-Dose Inhalers (MDIs)
• Smart Dry Powder Inhalers (DPIs)
• Smart Nebulisers
• Add-on Sensors and Clip Devices
• Companion Digital Platforms

By Disease Indication

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Other Respiratory Conditions

By End User

• Hospitals and Clinics
• Home Care Settings
• Ambulatory Care Centres
• Public Health Programme Channels
• Private Insurance Networks

By Country

• Brazil
• Colombia
• Chile
• Argentina
• Peru
• Rest of South America

Frequently Asked Questions

Q1. Which regulatory agency must smart inhaler manufacturers register with first in South America? ▼

Brazil's ANVISA is the mandatory first registration point for any manufacturer targeting South America, given Brazil's dominance of regional procurement volumes. ANVISA's Class III pathway under RDC 751/2022 governs all connected inhalers with SaMD components.

Q2. Does Brazil's SUS formulary currently include smart inhalers as reimbursable devices? ▼

Smart inhalers are not yet universally listed on the SUS Relação Nacional de Medicamentos Essenciais (RENAME), but connected device-compatible drug formulations are progressively included through Farmácia Popular updates. Full device reimbursement requires separate CONITEC health technology assessment approval.

Q3. What is the compliance timeline for ANVISA's planned 2026 post-market surveillance requirements? ▼

ANVISA's 2026 revision to RDC 751/2022 will require manufacturers of Class III devices to submit Periodic Safety Update Reports on an annual basis. Manufacturers with existing registrations will have an 18-month transition period from the date of final rule publication to achieve compliance.

Q4. How does Chile's GES plan create mandatory smart inhaler procurement obligations? ▼

The GES plan legally guarantees treatment for bronchial asthma in defined population groups, obligating CENABAST to procure qualifying devices at volumes sufficient to meet guaranteed coverage. Connected inhaler specifications entered GES technical annexes in 2023, making compliant smart inhalers eligible for these mandated tender volumes.

Q5. Does Argentina's price notification regime under ANMAT apply to smart inhalers sold through private channels? ▼

Yes, ANMAT's Observatorio de Precios requires manufacturers to notify and justify pricing for all registered medical devices, including smart inhalers, sold in both public and private channels. This effectively limits commercial pricing flexibility and discourages premium product launches outside reimbursed public procurement frameworks in Argentina.